These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 3273254)
21. The efficacy of various treatment modalities on aluminium associated bone disease. Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735 [TBL] [Abstract][Full Text] [Related]
22. [Effect of long-term lithium therapy on the pigment epithelium and optic nerve]. Schmidt-Betschel W; Aust W Ophthalmologe; 1994 Apr; 91(2):198-200. PubMed ID: 8012137 [TBL] [Abstract][Full Text] [Related]
23. Mucormycosis--a new risk of deferoxamine therapy in dialysis patients with aluminum or iron overload? Goodill JJ; Abuelo JG N Engl J Med; 1987 Jul; 317(1):54. PubMed ID: 3587314 [No Abstract] [Full Text] [Related]
24. Desferrioxamine related maculopathy: a case report. Arora A; Wren S; Gregory Evans K Am J Hematol; 2004 Aug; 76(4):386-8. PubMed ID: 15282675 [TBL] [Abstract][Full Text] [Related]
25. [Pathologic pigmentation and change in the electrical activity of the retina in dialyzed patients]. Svĕrák J; Peregrin J; Hejcmanová D Cas Lek Cesk; 1986 Jan; 125(3):77-9. PubMed ID: 3948219 [No Abstract] [Full Text] [Related]
26. Clearance of aluminum by hemodialysis: effect of desferrioxamine. Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984 [No Abstract] [Full Text] [Related]
27. Ocular abnormalities associated with advanced kidney disease and hemodialysis. Evans RD; Rosner M Semin Dial; 2005; 18(3):252-7. PubMed ID: 15934974 [TBL] [Abstract][Full Text] [Related]
28. Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results. Kovarik J; Irschik H; Graf H; Woloszczuk W; Meisinger V; Linkesch W; Stummvoll HK Contrib Nephrol; 1985; 49():44-55. PubMed ID: 3830570 [TBL] [Abstract][Full Text] [Related]
29. Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol Dial Transplant; 1993; 8 Suppl 1():1-4. PubMed ID: 8389013 [No Abstract] [Full Text] [Related]
30. The use of desferrioximine in dialysis-associated aluminium disease. Ackrill P; Day JP Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177 [No Abstract] [Full Text] [Related]
31. Clinical and electrophysiological features of tilted disc syndrome. Hamada T; Tsukada T; Hirose T Jpn J Ophthalmol; 1987; 31(2):265-73. PubMed ID: 3499535 [TBL] [Abstract][Full Text] [Related]
32. Deferoxamine does not increase the risk for bacteremia in hemodialysis patients. Tielemans C; Boelaert J; Vergauwe P; van Roost G; Segaert M; van Frachen B; Lenclud C Nephron; 1989; 53(3):276-7. PubMed ID: 2797349 [No Abstract] [Full Text] [Related]
33. [Eye pathology in chronic renal failure]. Svĕrák J; Peregrin J; Hejcmanová D; Rozsíval P; Kuba M; Erben J Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1984; 27(3):261-356. PubMed ID: 6599597 [No Abstract] [Full Text] [Related]
34. Cerebrospinal fluid aluminum levels following deferoxamine. Ellenberg R; King AL; Sica DA; Posner M; Savory J Am J Kidney Dis; 1990 Aug; 16(2):157-9. PubMed ID: 2382654 [TBL] [Abstract][Full Text] [Related]